COMMUNIQUÉS West-GlobeNewswire

Chimerix to Present at Cowen and Company 39th Annual Health Care Conference
04/03/2019
DURHAM, N.C., March 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that Timothy Trost, Chief [...]
Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
04/03/2019
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
04/03/2019
SYDNEY, Australia, March 04, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
04/03/2019
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation [...]
Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients
04/03/2019
OTTAWA, March 04, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, is pleased to announce [...]
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
04/03/2019
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a late-breaking [...]
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
04/03/2019
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - - Currently no available [...]
Orion Corporation: Managers' transactions - Virve Laitinen
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Virve Laitinen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Jari Karlson
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Jari Karlson Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Olli Huotari
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Olli Huotari Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Christer Nordstedt
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Christer Nordstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Orion Corporation: Managers' transactions - Liisa Hurme
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Markku Huhta-Koivisto
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Markku Huhta-Koivisto Orion Corporation has received the following disclosure under Market Abuse Regulation [...]
Orion Corporation: Managers' transactions - Satu Ahomäki
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Timo Lappalainen
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Timo Lappalainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]
Orion Group Financial Statement documents 2018 and Corporate Governance Statement published
04/03/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 4 MARCH 2019 at 12.00 EET Orion Group Financial Statement documents 2018 and Corporate Governance Statement published Orion Group's Financial Statement documents for 2018 have [...]
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2018 Financial Results
04/03/2019
Conference Call Scheduled for March 7, 2019 at 11:00 am EASTERN DUBLIN, Ireland, March 04, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the [...]
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
04/03/2019
Orphazyme A/S Company announcement No. 05/2019 Company Registration No. 32266355 Copenhagen, Denmark, March 1, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), [...]
Tecan schedules Analyst and Media Conference on March 11 to discuss Full-Year 2018 Financial Results
04/03/2019
Männedorf, Switzerland, March 4, 2019 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference to discuss the full-year 2018 financial results on Monday, March 11, 2019 at 09:00 am CET in [...]

Pages